Boehringer/Zealand Dual Agonist Achieves Promising Level Of Weight Loss
Drug Targets GLP-1 And Glucagon Receptors
Survodutide provides another obesity treatment option, albeit with gastrointestinal side effects that will need to be managed with slow titration to maintenance dosing, which will be tested in Phase III.
